Further large randomized clinical studies are highly desirable to confirm effects of “knocking on the FXR door” as a potential therapeutic approach in which change in bile acid pool size and composition may be exploited for the treatment of metabolic disorders. This evidence concerns the gene NR1H4 and Other metabolic disease.